Adult Clinical Trials

Lymphomas - Non-Hodgkin's lymphoma and Hodgkin's disease

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Lymphoma Clinical Trials Office at 919.681.4769.

7 trials identified.

CALGB 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Julie Warzecho, RN
Phone: 919.681.4769
Purpose: This research is being done in order to improve treatment outcomes in patients diagnosed with bulky, early stage Hodgkin lymphoma and to reduce the side effects that are associated with use of radiation used in current treatments. The chemotherapy treatment in this study consists of a combination of four drugs approved by the Food and Drug Administration (FDA): doxorubicin, bleomycin, vinblastine, and dacarbazine. This regimen (called ABVD) has been found to be effective in treating patients with Hodgkin lymphoma and is considered the standard of treatment used with radiation therapy in patients with bulky early stage Hodgkin lymphoma. As part of the evaluation of the effectiveness of the chemotherapy treatment, PET scans will be obtained during the course of therapy. The usefulness of this PET scan will be evaluated to determine whether radiation may be left out in the treatment of disease if the PET scan shows that the patient has responded to chemotherapy alone. The plan is to identify a group of patients using early PET scans in order to change to a chemotherapy treatment called BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). It is one of the most highly effective chemotherapy regimens for Hodgkin lymphoma, but is associated with more side effects than ABVD. Although it has become standard of care in Europe, its use has been more limited in the U.S. because of concerns about toxicity.
Reference Number: 00044123
View this trial at ClinicalTrials.gov

PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (CC-5013) PLUS R-CHOP CHEMOTHERAPY (R2-CHOP) VERSUS PLACEBO PLUS R-CHOP CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED ACTIVATED B-CELL TYPE DIFFUSE LARGE B-CELL LYMPHOMA
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Anne Beaven
Contact: Hematology Malignancy Oncology Research Clinical Trials Office
Phone: 919.681.4769
Purpose: To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL.
Reference Number: 00058584
View this trial at ClinicalTrials.gov

CALGB 51101: A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: LYMPHOMA CLINICAL TRIALS OFFICE
Phone: 919.681.4769
Purpose: The purpose of this study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma. Currently the best treatment for patients with primary CNS B-cell lymphoma is not known.
Reference Number: 00062558
View this trial at ClinicalTrials.gov

A Phase 1/2 Study Evaluating brentuximab vedotin in Combination With nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Anne Beaven
Contact: Hematology Malignancy Oncology Research Clinical Trials Office
Phone: 919.681.4769
Purpose: The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
Reference Number: 00064494
View this trial at ClinicalTrials.gov

A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Anne Beaven
Contact: LYMPHOMA CLINICAL TRIALS OFFICE
Phone: 919.681.4769
Purpose: The purpose of this randomized, open-label study is to evaluate the safety and efficacy of denintuzumab mafodotin plus RICE (rituximab, ifosfamide, carboplatin, and etoposide) when compared to RICE alone in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or Grade 3b follicular lymphoma. Eligible patients must also be candidates for autologous stem cell transplant. Patients will be randomly assigned in a 1:1 ratio to receive 3 cycles of study treatment with either denintuzumab mafodotin + RICE or RICE alone. The study will assess whether there is a difference between the 2 groups in the side effects that are reported and the number of patients who achieve complete remission at the end of their study treatment.
Reference Number: 00066502
View this trial at ClinicalTrials.gov

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Anne Beaven
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Purpose: The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.
Reference Number: 00073198
View this trial at ClinicalTrials.gov

PHASE 1 STUDY OF ACTR087, AUTOLOGOUS T LYMPHOCYTES EXPRESSING ANTIBODY COUPLED T-CELL RECEPTORS (CD16V-41BB-CD3), IN COMBINATION WITH RITUXIMAB, IN SUBJECTS WITH RELAPSED OR REFRACTORY CD20-POSITIVE B-CELL LYMPHOMA
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Anne Beaven
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Purpose: This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell lymphoma.
Reference Number: 00073532
View this trial at ClinicalTrials.gov